---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-110351"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T22:06:08.251123+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Armata Q3 loss from ops $7.8M; AP-SA02 Phase 2a shows efficacy, cGMP facility commissioned

## Summary
- Q3 2025 grant revenue $1.2M (vs $3.0M prior year); R&D expense $5.8M (vs $9.5M).
- Loss from operations $7.8M (vs $9.8M prior year); cash $14.8M as of Sep 30, 2025.
- Phase 2a diSArm study: AP-SA02 + BAT had higher cure rate at day 12 vs BAT alone; 100% response without relapse.
- 56,000 sq ft cGMP manufacturing facility in Los Angeles fully commissioned; enables scale-up for late-stage trials.
- Entered $15M secured credit agreement with Innoviva subsidiary, maturing January 2029, to fund AP-SA02 development.

## SEC filing metadata
- accession: 0001104659-25-110351
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465925110351/0001104659-25-110351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465925110351/armp-20251112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-110351
- JSON: https://secwatch.observer/filing/0001104659-25-110351.json
- Plain text: https://secwatch.observer/filing/0001104659-25-110351.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.